Ultragenyx Pharmaceutical RARE Software and Technology Licenses, Net
Software and Technology Licenses, Net at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's software and technology licenses, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's software and technology licenses, net?
- Ultragenyx Pharmaceutical (RARE) reported software and technology licenses, net of $61M in Q1 2026.
- How has Ultragenyx Pharmaceutical's software and technology licenses, net changed year-over-year?
- Ultragenyx Pharmaceutical's software and technology licenses, net decreased by 2.2% year-over-year, from $62.37M to $61M.
- What is the long-term trend for Ultragenyx Pharmaceutical's software and technology licenses, net?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's software and technology licenses, net has grown at a 46.8% compound annual growth rate (CAGR), from $8.81M to $60M.